<DOC>
	<DOC>NCT01102673</DOC>
	<brief_summary>The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK) and preliminary food effect of PF-04991532 following single escalating oral doses in healthy adult subjects.</brief_summary>
	<brief_title>Single Dose Study of PF-04991532 in Healthy Subjects</brief_title>
	<detailed_description>Safety/Tolerability and PK</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Healthy male and/or female (non childbearing potential) subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead ECG and clinical laboratory tests). Body Mass Index (BMI) of 17.5 to 35.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Any condition possibly affecting drug absorption (eg, gastrectomy). History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening. Use of tobacco or nicotinecontaining products in excess of the equivalent of 5 cigarettes per day. Selfreported history of hypoglycemia, or fasting laboratory glucose value &lt;/=80 mg/dL at screening or Day 0 of Period 1, confirmed by a single repeat if deemed necessary.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>phase 1</keyword>
	<keyword>safety and tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>T2DM</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>